Helius Medical Technologies, traded under the ticker HSDT, has secured reimbursement approval for its PoNS Device from a significant healthcare insurer, United Healthcare. The approved reimbursement package totals $18,100, which encompasses patient co-payment. This amount aligns with the approximate list price, while considering the device's out-of-network status.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Helius Medical Technologies Inc (HSDT, Financial) is $4.00 with a high estimate of $4.00 and a low estimate of $4.00. The average target implies an downside of 4.76% from the current price of $4.20. More detailed estimate data can be found on the Helius Medical Technologies Inc (HSDT) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Helius Medical Technologies Inc's (HSDT, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Helius Medical Technologies Inc (HSDT, Financial) in one year is $3.55, suggesting a downside of 15.48% from the current price of $4.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Helius Medical Technologies Inc (HSDT) Summary page.
